Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India To Set Lower Margin For MNC Drugs With Local Alternative

This article was originally published in PharmAsia News

Executive Summary

India's regulators plan to limit the ability of multinational drug makers to price their drugs in India if local alternatives are available. The government already is checking on that availability before approving the price of imported brand drugs. If a local alternative is available, the plan is to allow the foreign maker lower margins as a percentage of the landed cost, along with the therapeutic value and the drug's relationship to the quality of life. The government appears united on that aspect of price controls as its chief regulators continue to argue over a new policy. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts